RespireRx Pharmaceuticals has a quick ratio of 0.01. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for RespireRx Pharmaceuticals's Quick Ratio or its related term are showing as below:
RSPI's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.6 * Ranked among companies with meaningful Quick Ratio only.
RespireRx Pharmaceuticals (OTCPK:RSPI) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
RespireRx Pharmaceuticals Quick Ratio Related Terms
RespireRx Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, RespireRx Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RespireRx Pharmaceuticals Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RespireRx Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where RespireRx Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
RespireRx Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RespireRx Pharmaceuticals (RSPI) has a Quick Ratio of 0.01 as of Sep. 2023. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on RespireRx Pharmaceuticals and its competitors.
Is RespireRx Pharmaceuticals' Quick Ratio too high?
RespireRx Pharmaceuticals' current Quick Ratio is 0.01. The Biotechnology industry median Quick Ratio is 3.60. RespireRx Pharmaceuticals' value of 0.01 is 99.7% below this industry median. Overall, RespireRx Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RespireRx Pharmaceuticals' Quick Ratio compare to CNBX and NAVB?
RespireRx Pharmaceuticals' Quick Ratio of 0.01 can be compared against companies in the Biotechnology industry. The industry median Quick Ratio is 3.60. RespireRx Pharmaceuticals' value of 0.01 is 99.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RespireRx Pharmaceuticals's current Quick Ratio of 0.01 is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on RespireRx Pharmaceuticals and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RespireRx Pharmaceuticals's current Quick Ratio is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RespireRx Pharmaceuticals stock overvalued right now?
RespireRx Pharmaceuticals (RSPI) has a current Quick Ratio of 0.01. The current Quick Ratio is 0.01 and 99.7% below the Biotechnology industry median of 3.60. RespireRx Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For RespireRx Pharmaceuticals (RSPI), the current Quick Ratio is 0.01 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RespireRx Pharmaceuticals Inc is engaged in the discovery, value-added development, and commercialization through partners of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is in a 505(b)(2) development ideas for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; AMPAkines CX1739 for the treatment of bladder control and other conditions associated with spinal injury; CX717 for ADHD and CX1942 which is an injectable dosage formulation and GABAkines lead KRM-II-81 in preclinical development for treatment resistant epilepsy and non-opioid pain management.
12GF Score
Get the complete analysis for RSPI
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RSPI has been successfully added to your 
